<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28784/impact-of-lenalidomide-in-management-of-fl-and-mzl?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Impact of Lenalidomide in Management of FL and MZL

Name: Impact of Lenalidomide in Management of FL and MZL
Uploaded: 2019-06-27T07:32:51
Duration: 1 min 6 s
Description: Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas discusses how the approval of lenalidomide will impact how follicular lymphoma (FL) and marginal zone lymphoma (MZL) is managed.

00:01:06

Don

3 years 84 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28784/impact-of-lenalidomide-in-management-of-fl-and-mzl?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28784/impact-of-lenalidomide-in-management-of-fl-and-mzl?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28784/impact-of-lenalidomide-in-management-of-fl-and-mzl?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28784?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190627193251_fae5/video_190627193251_fae5.jpg?cache=15669161291678829655">Impact of Lenalidomide in Management of FL and MZL</a>

Link (BBCode):

[url=https://oncologytube.com/v/28784?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190627193251_fae5/video_190627193251_fae5.jpg?cache=15669161291678829655[/img]Impact of Lenalidomide in Management of FL and MZL[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Lymphoma

Description:

Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas discusses how the approval of lenalidomide will impact how follicular lymphoma (FL) and marginal zone lymphoma (MZL) is managed.